127 related articles for article (PubMed ID: 11987916)
1. Clinical relevance of MRD in children undergoing allogeneic stem cell transplantation for ALL.
Goulden N; Steward C
Best Pract Res Clin Haematol; 2002 Mar; 15(1):59-70. PubMed ID: 11987916
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A;
J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980
[TBL] [Abstract][Full Text] [Related]
3. Influence of transplantation regimen on prognostic significance of high-level minimal residual disease before allogeneic stem cell transplantation in children with ALL.
Schneider M; Hettinger K; Matthes-Martin S; Konrad M; Peters C; Gadner H; Panzer-Grümayer ER
Bone Marrow Transplant; 2001 Dec; 28(11):1087-9. PubMed ID: 11781621
[TBL] [Abstract][Full Text] [Related]
4. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
[TBL] [Abstract][Full Text] [Related]
5. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
Burkhardt B; Reiter A; Landmann E; Lang P; Lassay L; Dickerhoff R; Lakomek M; Henze G; von Stackelberg A
J Clin Oncol; 2009 Jul; 27(20):3363-9. PubMed ID: 19433688
[TBL] [Abstract][Full Text] [Related]
6. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lee S; Kim YJ; Chung NG; Lim J; Lee DG; Kim HJ; Min CK; Lee JW; Min WS; Kim CC
Cancer; 2009 Feb; 115(3):561-70. PubMed ID: 19117346
[TBL] [Abstract][Full Text] [Related]
7. Is there a role for minimal residual disease levels in the treatment of ALL patients who receive allogeneic stem cells?
Schilham MW; Balduzzi A; Bader P;
Bone Marrow Transplant; 2005 Mar; 35 Suppl 1():S49-52. PubMed ID: 15812531
[TBL] [Abstract][Full Text] [Related]
8. The role of allogeneic stem cell transplantation for adult acute lymphoblastic leukemia.
Paulson K; Szwajcer D; Seftel MD
Transfus Apher Sci; 2011 Apr; 44(2):197-203. PubMed ID: 21330213
[TBL] [Abstract][Full Text] [Related]
9. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.
Andersen NS; Pedersen LB; Laurell A; Elonen E; Kolstad A; Boesen AM; Pedersen LM; Lauritzsen GF; Ekanger R; Nilsson-Ehle H; Nordström M; Fredén S; Jerkeman M; Eriksson M; Väärt J; Malmer B; Geisler CH
J Clin Oncol; 2009 Sep; 27(26):4365-70. PubMed ID: 19652064
[TBL] [Abstract][Full Text] [Related]
10. [Minimal residual disease in childhood acute lymphoblastic leukemia: diagnosis of the 21 century].
Szczepański T; Sońta-Jakimczyk D; Van Dongen JJ
Przegl Lek; 2003; 60 Suppl 5():1-4. PubMed ID: 14574999
[TBL] [Abstract][Full Text] [Related]
11. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.
Maurillo L; Buccisano F; Del Principe MI; Del Poeta G; Spagnoli A; Panetta P; Ammatuna E; Neri B; Ottaviani L; Sarlo C; Venditti D; Quaresima M; Cerretti R; Rizzo M; de Fabritiis P; Lo Coco F; Arcese W; Amadori S; Venditti A
J Clin Oncol; 2008 Oct; 26(30):4944-51. PubMed ID: 18606980
[TBL] [Abstract][Full Text] [Related]
12. Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group.
Krejci O; van der Velden VH; Bader P; Kreyenberg H; Goulden N; Hancock J; Schilham MW; Lankester A; Révész T; Klingebiel T; van Dongen JJ
Bone Marrow Transplant; 2003 Oct; 32(8):849-51. PubMed ID: 14520434
[No Abstract] [Full Text] [Related]
13. Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse.
Pulsipher MA; Bader P; Klingebiel T; Cooper LJ
Biol Blood Marrow Transplant; 2009 Jan; 15(1 Suppl):62-71. PubMed ID: 19147081
[TBL] [Abstract][Full Text] [Related]
14. Molecular analysis of minimal residual disease in adult acute lymphoblastic leukaemia.
Foroni L; Hoffbrand AV
Best Pract Res Clin Haematol; 2002 Mar; 15(1):71-90. PubMed ID: 11987917
[TBL] [Abstract][Full Text] [Related]
15. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia.
Campana D; Coustan-Smith E
Best Pract Res Clin Haematol; 2002 Mar; 15(1):1-19. PubMed ID: 11987913
[TBL] [Abstract][Full Text] [Related]
16. Minimal residual disease as a surrogate marker for risk assignment to ALL patients.
Cazzaniga G; Gaipa G; Rossi V; Biondi A
Rev Clin Exp Hematol; 2003 Sep; 7(3):292-323. PubMed ID: 15024971
[TBL] [Abstract][Full Text] [Related]
17. Autologous stem cell transplant in ALL: who should we be transplanting in first remission?
Mato AR; Luger SM
Bone Marrow Transplant; 2006 Jun; 37(11):989-95. PubMed ID: 16633362
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate in combination with chemotherapy in four children with de novo and advanced stage Philadelphia chromosome-positive acute lymphoblastic leukemia.
Fuster JL; Bermúdez M; Galera A; Llinares ME; Calle D; Ortuño FJ
Haematologica; 2007 Dec; 92(12):1723-4. PubMed ID: 18056006
[TBL] [Abstract][Full Text] [Related]
19. Increasing risk of relapse after allogeneic stem cell transplant for adult acute lymphoblastic leukemia in > or = 2nd complete remission induced by highly intensive chemotherapy.
Mengarelli A; Iori AP; Cerretti R; Cerilli L; Romano A; Arcese W
Haematologica; 2002 Jul; 87(7):782-4. PubMed ID: 12091136
[TBL] [Abstract][Full Text] [Related]
20. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J
Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
